New generation weight reducing medications, such as glucagon-like peptide-1 agonists, with potentially beneficial effects on both diabetes and chronic kidney disease, might be important and cost beneficial for obese patients on PD to reduce antimicrobial use and infections (23). This evidence concerns the gene GCG and chronic kidney disease.